Facon T.; Dimopoulos M.A.; Meuleman N.; Belch A.; Mohty M.; Chen W.-M.; Kim K.; Zamagni E.; Rodriguez-Otero P.; Renwick W.; Rose C.; Tempescul A.; Boyle E.; Manier S.; Attal M.; Moreau P.; Macro M.; Leleu X.; Lorraine Chretien M.; Ludwig H.; Guo S.; Sturniolo M.; Tinel A.; Silvia Monzini M.; Costa B.; Houck V.; Hulin C.; Yves Mary J., A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial, «LEUKEMIA», 2020, 34, pp. 224 - 233 [Scientific article]
Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P., Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, «THE LANCET. HAEMATOLOGY», 2020, 7, pp. e456 - e468 [Scientific article]
Kastritis E.; Leleu X.; Arnulf B.; Zamagni E.; Cibeira M.T.; Kwok F.; Mollee P.; Hajek R.; Moreau P.; Jaccard A.; Schonland S.O.; Filshie R.; Nicolas-Virelizier E.; Augustson B.; Mateos M.-V.; Wechalekar A.; Hachulla E.; Milani P.; Dimopoulos M.A.; Fermand J.-P.; Foli A.; Gavriatopoulou M.; Klersy C.; Palumbo A.; Sonneveld P.; Erik Johnsen H.; Merlini G.; Palladini G., Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis, «JOURNAL OF CLINICAL ONCOLOGY», 2020, 38, pp. 3252 - 3260 [Scientific article]
Tacchetti P.; Pantani L.; Patriarca F.; Petrucci M.T.; Zamagni E.; Dozza L.; Galli M.; Di Raimondo F.; Crippa C.; Boccadoro M.; Barbato S.; Tosi P.; Narni F.; Montefusco V.; Testoni N.; Spadano A.; Terragna C.; Pescosta N.; Marzocchi G.; Cellini C.; Galieni P.; Ronconi S.; Gobbi M.; Catalano L.; Lazzaro A.; De Sabbata G.; Cangialosi C.; Ciambelli F.; Musto P.; Elice F.; Cavo M.; Fanin R.; Foa' R.; Rambaldi A.; Rossi G.; Leoni P.; Corradini P.; Torelli G.; Fioritoni G.; Cortelazzo S.; Lambertenghi Deliliers G.; La Nasa G.; Zaccaria A.; De Fabritiis P.; Cascavilla N.; Bosi A.; Semenzato G.; Gugliotta L.; Gherlinzoni F.; Angelucci E.; Martelli M.F.; Petti M.C.; Leone G.; Carella A.M.; Ciceri F.; Santoro A.; Ferrara F.; Nobile F.; D'Arco A.M.; Levis A.; Guardigni L.; Gallamini A.; Fattori P.P.; Morandi S.; Amadori D.; Rotoli B.; Mirto S.; Paladini G.; Mozzana R.; Pinotti G.; Rodeghiero F.; Cantore N.; Pavone V.; Pogliani E.M.; Liberati A.M.; Majolino I.; Amadori S.; Lauria F.; Aglietta M., Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study, «THE LANCET. HAEMATOLOGY», 2020, 7, pp. 861 - 873 [Scientific article]
Jamet B.; Zamagni E.; Nanni C.; Bailly C.; Carlier T.; Touzeau C.; Michaud A.-V.; Moreau P.; Bodet-Milin C.; Kraeber-Bodere F., Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2020, 21, Article number: 5406 , pp. 1 - 14 [Scientific article]Open Access
Michaud-Robert A.-V.; Zamagni E.; Carlier T.; Bailly C.; Jamet B.; Touzeau C.; Moreau P.; Kraeber-Bodere F.; Nanni C.; Bodet-Milin C., Glucose metabolism quantified by suvmax on baseline fdg-pet/ct predicts survival in newly diagnosed multiple myeloma patients: Combined harmonized analysis of two prospective phase iii trials, «CANCERS», 2020, 12, Article number: 2532 , pp. 1 - 10 [Scientific article]Open Access
Mateos M.-V.; Kumar S.; Dimopoulos M.A.; Gonzalez-Calle V.; Kastritis E.; Hajek R.; De Larrea C.F.; Morgan G.J.; Merlini G.; Goldschmidt H.; Geraldes C.; Gozzetti A.; Kyriakou C.; Garderet L.; Hansson M.; Zamagni E.; Fantl D.; Leleu X.; Kim B.-S.; Esteves G.; Ludwig H.; Usmani S.; Min C.-K.; Qi M.; Ukropec J.; Weiss B.M.; Rajkumar S.V.; Durie B.G.M.; San-Miguel J., International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM), «BLOOD CANCER JOURNAL», 2020, 10, pp. 102 - 102 [Scientific article]Open Access
Morvan L.; Nanni C.; Michaud A.-V.; Jamet B.; Bailly C.; Bodet-Milin C.; Chauvie S.; Touzeau C.; Moreau P.; Zamagni E.; Kraeber-Bodere F.; Carlier T.; Mateus D., Learned Deep Radiomics for Survival Analysis with Attention, in: Lecture Notes in Computer Science, Cham, Springer Nature Switzerland, 2020, pp. 35 - 45 [Chapter or essay]
Zappulo, F; Donati, G; Comai, G; Bini, C; Angeletti, A; Scrivo, A; Zamagni, E; Cavo, M; La Manna, G, LONG-TERM OUTCOME OF KIDNEY TRANSPLANTATION IN PLASMA CELLS DYSCRASIAS, in: Nephrology Dialysis Transplantation, «NEPHROLOGY DIALYSIS TRANSPLANTATION», 2020, 35, pp. 2010 - 2010 (atti di: 57th ERA-EDTA Congress, Milan, Italy, 6 -9 June 2020) [Contribution to conference proceedings]
Mancuso K.; Tacchetti P.; Pantani L.; Rocchi S.; Rizzello I.; Caratozzolo I.; De Cicco G.; Fusco A.; Testoni N.; Terragna C.; Marzocchi G.; Martello M.; Borsi E.; Dozza L.; Cavo M.; Zamagni E., Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma, «BONE MARROW TRANSPLANTATION», 2020, 55, pp. 1865 - 1867 [Scientific article]
Elena Zamagni; Paola Tacchetti; Simona Barbato; Michele Cavo, Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients, «JOURNAL OF CLINICAL MEDICINE», 2020, 9, Article number: 3519 , pp. 1 - 9 [Scientific article]Open Access
Zamagni E.; Tacchetti P.; Deias P.; Patriarca F., The role of monoclonal antibodies in smoldering and newly diagnosed transplant-eligible multiple myeloma, «PHARMACEUTICALS», 2020, 13, Article number: 451 , pp. 1 - 12 [Scientific article]Open Access
Donati, Gabriele; Zappulo, Fulvia; Croci Chiocchini, Anna Laura; Comai, Giorgia; Zamagni, Elena; La Manna, Gaetano, Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report, «HEMODIALYSIS INTERNATIONAL», 2019, 23, pp. E97 - E99 [Scientific article]
Nanni C.; Zamagni E., Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma, «PET CLINICS», 2019, 14, pp. 383 - 389 [Scientific article]
Cavo M.; Tacchetti P.; Zamagni E., Front-line treatment of multiple myeloma, «HEMASPHERE», 2019, 3, pp. 127 - 130 [Scientific article]
